Defunct Company
Total Trials
3
As Lead Sponsor
As Collaborator
0
Total Enrollment
108
NCT01998659
Single Ascending Oral Dose Phase I Study With Px-102
Phase: Phase 1
Role: Lead Sponsor
Start: Sep 30, 2011
Completion: Dec 31, 2011
NCT01998672
Multiple Ascending Oral Dose Phase I Study With Px-102
Start: Feb 29, 2012
Completion: Oct 31, 2012
NCT01999101
Safety Pilot Study of Farnesoid X Receptor (FXR) Agonist in Non-alcoholic Fatty Liver Disease (NAFLD) Patients
Phase: Phase 2
Start: Oct 31, 2013
Completion: Jun 30, 2016